<p>
    INDILIV (Individualized Immunosuppression after Liver Transplant) Year 1:
</p>
<p>
    Initiating Immunosuppression (IS):
</p>
<ul>
    <li data-list-item-id="eb655894003ca8f0ca3efe7b044bc9990">
         Select IS based on the recipient’s rejection risk.
    </li>
    <li data-list-item-id="e4013b26c5720acaff3c82d779797062f">
         Tailor agent choice considering renal function, neurologic status, cytopenias, and gastrointestinal tolerance.
    </li>
    <li data-list-item-id="e6989bb8b7b9e841e17c05a50da3db304">
         All patients receive 500 mg IV solumedrol intraoperatively during the anhepatic phase, followed by a tapering steroid regimen.
    </li>
    <li data-list-item-id="e9dca01435d253ce1ef8858fd6fd040a4">
         Tacrolimus levels should be checked daily until target level is reached, then every other day to avoid overcorrection.
    </li>
    <li data-list-item-id="e71afc8aaf52b93816a24118d68b1450c">
         Modify calcineurin inhibitor (CNI) initiation, dosing, and targets based on neurological status.
    </li>
</ul>
<p>
    <strong>Immunosuppression Medications</strong>
</p>
<p>
    1. Corticosteroid Tapering Protocol:
</p>
<ul>
    <li data-list-item-id="eeaaa11cb97e1c9fe5566821640a7b527">
         POD 0: Methylprednisolone 500 mg IV (anhepatic phase)
    </li>
    <li data-list-item-id="eb5c9e12b96ead11c235581725f721ead">
         POD 1–5: Methylprednisolone IV taper (200 → 160 → 120 → 80 → 40 mg)
    </li>
    <li data-list-item-id="ebb7b915b61f886deeb02e610bab080a1">
         POD 6: Start oral prednisone 20 mg daily, continue for 3 weeks
    </li>
</ul>
<p>
    Tapering schedule:
</p>
<ul>
    <li data-list-item-id="e2fe1f5313f18529bf8b973b7226782a3">
         15 mg daily × 2 weeks
    </li>
    <li data-list-item-id="e42f64a904f81dc72f41997c0e6bf2ef5">
         10 mg daily × 2 weeks
    </li>
    <li data-list-item-id="e7778a40843b11687e28f9954d70827b2">
         7.5 mg daily × 2 weeks
    </li>
    <li data-list-item-id="e1be15ad0843d66b68590a7554de6fd87">
         5 mg daily × 2 weeks
    </li>
    <li data-list-item-id="e765c2cb11abb722becdd82f57ca6b2d8">
        <p>
             Then taper to 4, 3, 2, 1 mg weekly or 2.5 mg daily × 4 weeks, then stop
        </p>
        <p>
            Note: Consider adrenal insufficiency risk when tapering
        </p>
    </li>
</ul>
<p>
    2. Tacrolimus (Tac):
</p>
<ul>
    <li data-list-item-id="e67cc3aab8412d66ee673d32c40f4623d">
         Start within 12 hours post-transplant, aiming for Tac levels &gt;7 within 2–3 days
    </li>
    <li data-list-item-id="e9ed3f9cb40c0bc2e9dad95ba6bc13dc8">
         Starting doses (to be adjusted individually):
        <ul>
            <li data-list-item-id="e11a171165dfe6c25b25477dc44fe48b2">
                 &lt;50 kg: 1 mg BID
            </li>
            <li data-list-item-id="e4869701bfc2758502c2b60339a523b6d">
                 50–80 kg: 2 mg BID
            </li>
            <li data-list-item-id="eedd604eb6fc0c642a89f7dcf2b51ff6a">
                 80 kg: 3 mg BID
            </li>
        </ul>
    </li>
    <li data-list-item-id="e763e9691b19e7e5c843bef9dbb7b8e74">
         Consider initiating Tac before OR if appropriate
    </li>
    <li data-list-item-id="e7a78cb5d4c82bbffc636aa1802a600e7">
         No delay for initiation even if GFR is low
    </li>
</ul>
<p>
    &nbsp;3. Biopsy Protocol:
</p>
<ul>
    <li data-list-item-id="ef878fb248983d1efff3bc12942aaee7e">
         Backtable and post-reperfusion liver biopsies should be collected and submitted to the MOT biobank
    </li>
</ul>
<p>
    4. Basiliximab Induction:
</p>
<ul>
    <li data-list-item-id="ea5e5a55803944656b7c7c61cb470e923">
         Dose: 20 mg IV on POD 0 and POD 4
    </li>
    <li data-list-item-id="eee4ff4e2e1af01da6ccbf65a94a2c61c">
         Indications:
        <ul>
            <li data-list-item-id="e60d19bade05e87b77c84c7078caaed61">
                 GFR &lt;60 or on dialysis pre-transplant
            </li>
            <li data-list-item-id="e103d605003cefa3442db46eeff6166d4">
                 Pre-existing or expected neurotoxicity
            </li>
            <li data-list-item-id="ee4dabb2830aaefb66b78c55906d772d1">
                 High rejection risk patients&nbsp;
            </li>
        </ul>
    </li>
</ul>

<figure class="table">
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Patient&nbsp;
                </td>
                <td>
                    0-3 Months&nbsp;
                </td>
                <td>
                    4-6 months&nbsp;
                </td>
                <td>
                    7-12 months&nbsp;
                </td>
                <td>
                    1 year&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    <p>
                        High Risk Patients:
                    </p>
                    <ul>
                        <li data-list-item-id="eac8fce85df365537f333347ad69efca8">
                             Autoimmune liver diseases: PBC, AIH, PSC
                        </li>
                        <li data-list-item-id="ea5763a62ec01b8c76be937cbe3c66446">
                             Age &lt;25 years
                        </li>
                        <li data-list-item-id="ee6ab381ef22ca9b1af2085acbc22aa9a">
                             Re-transplant for non-vascular, non-biliary causes (e.g., recurrent disease)
                        </li>
                        <li data-list-item-id="e4115584f1915f531058ba5a83eb95237">
                             Fulminant hepatic failure
                        </li>
                        <li data-list-item-id="e24ed0d7fda091ecfa305c73f0f374314">
                             High MHC-eplet mismatch
                        </li>
                        <li data-list-item-id="e8dc1a26e488fe02ffcf5514fe4d41db5">
                             Pre-transplant donor-specific antibodies (DSA)&nbsp;
                        </li>
                    </ul>
                </td>
                <td>
                    <p>
                        Tac 8-12
                    </p>
                    <p>
                        MYF 540 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        Tac 6-8
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        Tac 6-8
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td rowspan="2">
                    Biopsy&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Low risk: All other recipients &nbsp;
                </td>
                <td>
                    <p>
                        Tac 6-8
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        Tac 4-6
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        Tac 4-6
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
            </tr>
        </tbody>
    </table>
</figure>

<p>
    *Note:
</p>
<ul>
    <li data-list-item-id="e75dc06ff8eb9d606b2943e920256091c">
         For 0-3 months
        <ul>
            <li data-list-item-id="e9c45feacbe5204163bcf85b9c81eda3b">
                 GFR 30–60: Target Tacrolimus level 6–8 ng/mL; start at 50% of standard dose. Do not delay Tac. Initiate dapagliflozin 10 mg daily before discharge.
            </li>
            <li data-list-item-id="e9b5c884a35dc4973547fa2b6fba2554e">
                 GFR 30–60: Target Tac 6–8 ng/mL; up-titrate Mycophenolate (MYF) to 540–720 mg BID. No delay in Tac. Start dapagliflozin 10 mg daily pre-discharge.
            </li>
            <li data-list-item-id="e68a6a6633de09a33e74ef7e5aea848ce">
                 GFR &lt;30: Target Tac 4–6 ng/mL; up-titrate MYF to 540–720 mg BID. No Tac delay. Adjust Tac to 3–5 ng/mL after month 3.
            </li>
        </ul>
    </li>
    <li data-list-item-id="e2eb69e191240bb63ea14173404cc58d4">
         MYF is primarily adjusted based on WBC count (if platelets &gt;25,000). MYF trough levels above 180 ng/mL are not clinically impactful.
        <ul>
            <li data-list-item-id="e812c5f694dbc145bf507731c981eae06">
                 If MYF is contraindicated or not tolerated, increase Tacrolimus target by ~30% (e.g., to substitute for 360 mg MYF).
            </li>
        </ul>
    </li>
    <li data-list-item-id="e5fb990d3bd669161a812c1d95636fa8a">
         Target drug levels should be clearly documented in EPIC under “thresholds.” &nbsp;
    </li>
</ul>

<p>
    Alternative to Tac:
</p>
<p>
    Cyclosporine is reserved for patients who cannot tolerate tacrolimus, such as those with significant CNS side effects unmanageable by dose reduction, tacrolimus allergy, or possibly patients with PBC. It is considered a second-line agent, and its use should remain exceptional.
</p>
<p>
    Dosing Guidelines:
</p>
<ul>
    <li data-list-item-id="ead8d975810ca16cca81fd2a2fb1e1cd9">
         Standard dose: 50–100 mg PO BID on transplant day.
    </li>
    <li data-list-item-id="e18ea27c281fb1375979e11133a2620c8">
         Lower dose (50 mg BID): For patients with delirium, malnutrition, AKI, or on hemodialysis.
    </li>
    <li data-list-item-id="ea78414a373a1e36c53b186a479dd0313">
         Higher dose (200 mg BID): For young patients or those with BMI &gt;35.
    </li>
    <li data-list-item-id="e18094ef49b08d7731c6508be09ca8dd2">
         IV conversion: 15 mg/kg BID (oral:IV = 3:1 ratio).
    </li>
</ul>
<p>
    Monitoring: While C2 levels best correlate with total drug exposure (AUC), they are rarely timed correctly, so trough levels are preferred in practice.&nbsp;
</p>
<figure class="table">
<table class="table table-bordered">         <tbody>             <tr class="table-secondary">
                <td>
                    Patient&nbsp;
                </td>
                <td>
                    0-3 Months&nbsp;
                </td>
                <td>
                    4-6 months&nbsp;
                </td>
                <td>
                    7-12 months&nbsp;
                </td>
                <td>
                    1 year&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    <p>
                        High Risk Patients:
                    </p>
                    <ul>
                        <li data-list-item-id="e15a0fb16fcbe19b86c8fa5f10e1169d6">
                             Autoimmune liver diseases: PBC, AIH, PSC
                        </li>
                        <li data-list-item-id="e2d2473101a9b6760f2f97f17b4385fb4">
                             Age &lt;25 years
                        </li>
                        <li data-list-item-id="e88ea39935f577c872df725b3aa700d93">
                             Re-transplant for non-vascular, non-biliary causes (e.g., recurrent disease)
                        </li>
                        <li data-list-item-id="e4dbfba21aca89dddee91c1c53f549b56">
                             Fulminant hepatic failure
                        </li>
                        <li data-list-item-id="ea5cbecc0fb960919b11f4ffddeec0466">
                             High MHC-eplet mismatch
                        </li>
                        <li data-list-item-id="ed1d5cd1213889594a4f76d1e74b71784">
                             Pre-transplant donor-specific antibodies (DSA)&nbsp;
                        </li>
                    </ul>
                </td>
                <td>
                    <p>
                        CyA 150-200
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        CyA 100-150
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        CyA 100-150
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td rowspan="2">
                    Biopsy&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Low risk: All other recipients &nbsp;
                </td>
                <td>
                    <p>
                        CyA 120-160
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        CyA 100-120
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
                <td>
                    <p>
                        CyA 70-100
                    </p>
                    <p>
                        MYF 360 bid&nbsp;
                    </p>
                </td>
            </tr>
        </tbody>
    </table>
</figure>